Filtered By:
Drug: Colchicine
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 88 results found since Jan 2013.
Colchicine in Neurosurgery.
CONCLUSION: Colchicine is a drug that over the years has shown promising results in certain neurosurgical entities. Its derivatives or potential colchicine-like agents might have a more significant place in neurosurgical practice.
PMID: 29336254 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - January 14, 2018 Category: Drugs & Pharmacology Authors: Evangelos D, Dimitrios G, Marios TS Tags: Curr Pharm Des Source Type: research
Colchicine in post-operative Atrial Fibrillation: a review.
Abstract
Post-operative atrial fibrillation (POAF) is a frequent entity increasing hospitalization duration, stroke and mortality. In the recent years, a few studies have sought to investigate the potential effect of colchicine in POAF prevention after cardiac surgery or catheter pulmonary vein isolation for AF. In the present review article, we intend to provide a synopsis of clinical practice guidelines, summarize and critically approach current evidence for or against colchicine as a means of POAF prevention.
PMID: 29336253 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - January 14, 2018 Category: Drugs & Pharmacology Authors: Vrachatis DA, Kossyvakis C, Angelidis C, Panagopoulou V, Sarri EK, Giotaki S, Siasos G, Vavuranakis M, Deftereos SG Tags: Curr Pharm Des Source Type: research
T effect of low dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design and baseline characteristics
ConclusionThe LoDoCo2 Trial will provide information on the efficacy and safety of low dose colchicine for secondary prevention in patients with stable coronary artery disease.
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research
Behcet's Disease With Cerebral Artery Infarction Caused by Cerebral Arteritis as an Early Symptom Only With Elevated Interleukin-8
Conclusion: This case demonstrates that neurological involvement might be an early symptom of BD. IL-8 could act as a novel target for the treatment of BD theoretically and probably play a key role in disease recovery.
Source: Frontiers in Neurology - October 21, 2019 Category: Neurology Source Type: research
The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics
ConclusionThe LoDoCo2 Trial will provide information on the efficacy and safety of low-dose colchicine for secondary prevention in patients with stable coronary artery disease.
Source: American Heart Journal - November 7, 2019 Category: Cardiology Source Type: research
Colchicine cuts odds of new heart attack, stroke in heart attack survivors
(Reuters Health) - The inflammation-fighting drug colchicine, already a treatment for gout, dramatically reduces the odds of future cardiovascular problems in people who have just survived a heart attack, a large new study has concluded.
Source: Reuters: Health - November 18, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Drug used to treat gout cuts odds of new heart attack, stroke in heart attack survivors
The inflammation-fighting drug colchicine, already a treatment for gout, dramatically reduces the odds of future cardiovascular problems in people who have just survived a heart attack, a large new study by a Montreal researcher has concluded.
Source: CBC | Health - November 18, 2019 Category: Consumer Health News Tags: News/Health Source Type: news
Cheap, Older Gout Drug Could Be a Lifesaver After Heart Attack
In the new trial, colchicine reduced by as much as 34% a heart attack survivor's combined risk of either dying from heart disease or having cardiac arrest, a heart attack, a stroke or angioplasty.
Source: WebMD Health - November 18, 2019 Category: Consumer Health News Source Type: news
Targeting Inflammation to Reduce Residual Cardiovascular Risk
AbstractPurpose of ReviewPatients with established cardiovascular disease are at high risk for recurrent myocardial infarction, stroke, and cardiovascular death. The termresidual risk refers to this risk that persists, even after optimal treatment. Considerable progress has been made to understand the biological basis of residual risk and to devise therapies that can safely and effectively reduce risk. The presence of ongoing subclinical vascular inflammation is known to be a marker of elevated residual risk, and reductions in measures of vascular inflammation predict improved outcome in these patients.Recent FindingsRecen...
Source: Current Atherosclerosis Reports - September 2, 2020 Category: Cardiology Source Type: research
Colchicine: An ancient drug with multiple benefits.
Abstract
The history of colchicine dates to ancient Egyptians when it was used for alleviation of swelling and pain. Although its popularity varied throughout the years, colchicine has been a mainstay for the treatment of several diseases, mainly rheumatic and cardiac ones. The mechanism of action of the drug involves several intracellular and extracellular targets, although interaction with tubulin is the most described. Based on several clinical trials and meta-analyses, colchicine is safely recommended as a monotherapy or as an add-on for the treatment and prevention of recurrent pericarditis, postpericardiotom...
Source: Current Pharmaceutical Design - October 23, 2020 Category: Drugs & Pharmacology Authors: El Hasbani G, Jawad A, Uthman I Tags: Curr Pharm Des Source Type: research
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes
AbstractHyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a proinflammatory milieu. However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable coronary artery disease independent of lipid-lowering effects. There is resurging interest in colchicine following publication of the COLCOT, LoDoCo, LoDoCo2, LoDoCo-MI trials, and COLCORONA trial which will shed light on its utility in COVID-19. ...
Source: American Journal of Cardiovascular Drugs - December 28, 2020 Category: Cardiology Source Type: research
Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis
AbstractTo evaluate the efficacy and safety of colchicine for secondary prevention of coronary heart disease (CHD), relevant randomized controlled trials (RCTs) were identified by searching several databases from the creation date to August 31, 2020 and were reviewed. Eight eligible trials of colchicine therapy involving a total of 11, 463 patients were included (5, 776 subjects received colchicine, while 5, 687 subjects were in the respective control arms), and the outcome was reported as risk ratio (RR) and 95% confidence interval (CI), as the relative measure of association. Overall, the incidences of major adverse card...
Source: Internal and Emergency Medicine - January 5, 2021 Category: Emergency Medicine Source Type: research
Update on the Inflammatory Hypothesis of Coronary Artery Disease
AbstractPurpose of ReviewThe pathogenesis and progression of coronary artery disease (CAD) is now known to be largely driven by inflammation on top of the well-accepted role for the disequilibrium between cholesterol deposition and removal from the arterial wall. Recent clinical trials have supported the inflammatory hypothesis of CAD and will be discussed in this review.Recent FindingsThe clinical trial Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) found that treatment with canakinumab, an anti-interleukin-1 β agent, resulted in a reduction in non-fatal myocardial infarction, non-fatal stroke, or death...
Source: Current Cardiology Reports - January 6, 2021 Category: Cardiology Source Type: research
The Efficacy of Colchicine on Carotid Intima-Media Thickness: A Prospective Comparative Study
Inflammation plays an important role in the development of atherosclerotic vascular disease, which is the leading cause of morbidity and mortality in the adult population. Several clinical trials have shown that suppression of the inflammatory response can delay or decrease the atherosclerotic process. The aim of this study was to investigate carotid intima-media thickness (CIMT) between patients with chronic disease history plus gout using colchicine and patients with cardiovascular risk factors.
Source: Journal of Stroke and Cerebrovascular Diseases - December 30, 2020 Category: Neurology Authors: Ebru Yilmaz, Kadriye Halli Akay Source Type: research
Colchicine efficacy and safety for the treatment of cardiovascular diseases
AbstractThe emerging role of colchicine in the treatment of cardiovascular diseases is a strong demand for a comprehensive understanding of its efficacy and safety. This meta-analysis and systematic review aimed to study the efficacy in the reduction of adverse cardiovascular outcomes (CO), and the risk of colchicine-related adverse events (CRAEs). Fourteen thousand and nine eighty three patients from 22 randomized controlled trials (RCTs) were included, 9 in patients with coronary artery disease —CAD, 9 in patients with pericarditis, 4 in patients with atrial fibrillation—AF or heart failure. Colchicine was efficaciou...
Source: Internal and Emergency Medicine - March 11, 2021 Category: Emergency Medicine Source Type: research
